Comparing Ligand Pharmaceuticals (NASDAQ:LGND) & Septerna (NASDAQ:SEPN)

Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) and Septerna (NASDAQ:SEPN – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.

Risk & Volatility

Ligand Pharmaceuticals has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, Septerna has a beta of 2.2, suggesting that its share price is 120% more volatile than the S&P 500.

Earnings & Valuation

This table compares Ligand Pharmaceuticals and Septerna”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ligand Pharmaceuticals $268.09 million 21.40 $124.45 million $2.24 128.07
Septerna $45.95 million 39.95 -$48.88 million ($1.29) -29.93

Ligand Pharmaceuticals has higher revenue and earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ligand Pharmaceuticals and Septerna’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ligand Pharmaceuticals 20.27% 5.22% 2.74%
Septerna -61.29% -14.98% -10.03%

Analyst Recommendations

This is a summary of current recommendations and price targets for Ligand Pharmaceuticals and Septerna, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ligand Pharmaceuticals 0 1 8 0 2.89
Septerna 1 1 8 1 2.82

Ligand Pharmaceuticals presently has a consensus price target of $355.38, indicating a potential upside of 23.88%. Septerna has a consensus price target of $56.78, indicating a potential upside of 47.05%. Given Septerna’s higher probable upside, analysts clearly believe Septerna is more favorable than Ligand Pharmaceuticals.

Institutional & Insider Ownership

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 5.6% of Ligand Pharmaceuticals shares are held by insiders. Comparatively, 5.8% of Septerna shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Ligand Pharmaceuticals beats Septerna on 9 of the 14 factors compared between the two stocks.

About Ligand Pharmaceuticals

(Get Free Report)

Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.

About Septerna

(Get Free Report)

Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California. Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.